Abstract
Purpose
Deficiency of dihydropyrimidine dehydrogenase (DPD) has been associated with severe fluoropyrimidines (FP) toxicity. Mutations in DPD-coding gene (DPYD) were shown to increase the risk of severe toxicity in FP-treated cancer patients. However, the majority of DPYD alterations characterized in these patients has been considered as polymorphisms and known deleterious mutations are rare and present in only limited subgroup of patients with high toxicity. Recently, the common fragile site FRA1E was mapped within DPYD locus but intragenic rearrangements in DPYD gene were not studied so far.
Methods
We performed the analysis of intragenic rearrangements of DPYD using multiplex ligation-dependent probe amplification in 68 patients with high-grade gastrointestinal and/or hematological toxicity developed at the beginning of FP treatment.
Results
We did not detect any deletion/duplication of one or more DPYD exons in analyzed patients.
Conclusions
We assume that rearrangements in DPYD gene play insignificant role in the development of serious FP-related toxicity.
This is a preview of subscription content, log in via an institution to check access.
References
van Kuilenburg AB (2004) Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40:939–950
Diasio RB (1998) Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase. Br J Clin Pharmacol 46:1–4
Collie-Duguid ES, Etienne MC, Milano G et al (2000) Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 10:217–223
Maekawa K, Saeki M, Saito Y et al (2007) Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences. J Hum Genet 52:804–819
Schwab M, Zanger UM, Marx C et al (2008) Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU toxicity study group. J Clin Oncol 26:2131–2138
Bosch TM, Bakker R, Schellens JH et al (2007) Rapid detection of the DPYD IVS14 + 1G > A mutation for screening patients to prevent fluorouracil-related toxicity. Mol Diagn Ther 11:105–108
Johnson MR, Wang K, Tillmanns S et al (1997) Structural organization of the human dihydropyrimidine dehydrogenase gene. Cancer Res 57:1660–1663
Hormozian F, Schmitt JG, Sagulenko E et al (2007) FRA1E common fragile site breaks map within a 370kilobase pair region and disrupt the dihydropyrimidine dehydrogenase gene (DPYD). Cancer Lett 246:82–91
den Dunnen JT, White SJ (2006) MLPA and MAPH: sensitive detection of deletions and duplications. In: Ujhazy V (ed) Current protocols in human genetics, Wiley, New York, pp 7.14.1–7.14.20
Kleibl Z, Fidlerova J, Kleiblova P et al (2009) Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy. Neoplasma 56 (accepted)
MRC-Holland. http://www.mlpa.com/, SALSA MLPA kit P103 DPYD
Ploylearmsaeng SA, Fuhr U, Jetter A (2006) How may anticancer chemotherapy with fluorouracil be individualised? Clin Pharmacokinet 45:567–592
Maring JG, van Kuilenburg AB, Haasjes J et al (2002) Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. Br J Cancer 86:1028–1033
Ezzeldin HH, Diasio RB (2008) Predicting fluorouracil toxicity: can we finally do it? J Clin Oncol 26:2080–2082
Mercier C, Ciccolini J (2006) Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy. Clin Colorectal Cancer 6:288–296
Saif MW, Ezzeldin H, Vance K et al (2007) DPYD*2A mutation: the most common mutation associated with DPD deficiency. Cancer Chemother Pharmacol 60:503–507
van Kuilenburg AB, Meinsma R, Zoetekouw L et al (2002) High prevalence of the IVS14 + 1G > A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 12:555–558
Morel A, Boisdron-Celle M, Fey L et al (2006) Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther 5:2895–2904
Gross E, Busse B, Riemenschneider M et al (2008) Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients. PLoS ONE 3:e4003
Imyanitov EN, Moiseyenko VM (2007) Molecular-based choice of cancer therapy: realities and expectations. Clin Chim Acta 379:1–13
Acknowledgments
This study was supported by the grant of Internal Grant Agency of the Ministry of Health of the Czech Republic No. 1A8708-4/2005 and the Research Project of The Ministry of Education, Youth and Sports of the Czech Republic No. MSM0021620808.
Author information
Authors and Affiliations
Corresponding author
Additional information
I. Ticha, P. Kleiblova contributed equally to this work.
Rights and permissions
About this article
Cite this article
Ticha, I., Kleiblova, P., Fidlerova, J. et al. Lack of large intragenic rearrangements in dihydropyrimidine dehydrogenase (DPYD) gene in fluoropyrimidine-treated patients with high-grade toxicity. Cancer Chemother Pharmacol 64, 615–618 (2009). https://doi.org/10.1007/s00280-009-0970-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-009-0970-4